Armistice Capital’s CareDx CDNA Stock Holding History

Armistice Capital’s Portfolio CDNA Stock Details CDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,036,000	Closed	-$14.3M	–	313
2023 Q3	$14.3M	Sell	2,036,000 -1,288,000	-39%	-$11.9M	0.22%	75
2023 Q2	$28.3M	Buy	3,324,000 +188,000	+6%	+$1.57M	0.41%	49
2023 Q1	$28.7M	Buy	3,136,000 +2,636,000	+527%	+$33.7M	0.41%	50
2022 Q4	$5.71M	Buy	+500,000	New	+$7.41M	0.1%	94

Other funds holding CDNA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Armistice Capital's CDNA Position: Q4 2023 in Review

Armistice Capital sold out of CareDx (CDNA) in Q4 2023, closing a stake of 2,036,000 shares — an estimated $14.3M sold.

Armistice Capital first reported a position in CDNA in Q4 2022 and held it in 4 quarters. The position peaked at $28.7M in Q1 2023. 147 funds tracked by Wall St. Rank hold CDNA as of Q4 2023.

Armistice Capital reported no remaining CareDx position as of Q4 2023 after selling out during the quarter.
Armistice Capital sold 2,036,000 CareDx shares in Q4 2023, an estimated $14.3M.
Armistice Capital first reported a position in CareDx in Q4 2022 and held it in 4 quarters.
Armistice Capital's CareDx position peaked at $28.7M in Q1 2023.
147 funds tracked by Wall St. Rank held CareDx as of Q4 2023.

Based on Armistice Capital's 13F filing for Q4 2023, filed 13 Feb 2024.